, 2012 Marion Lyoen +4 more
openalex +1 more source
The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle
ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley +1 more source
30 A study of the prevalence of impaired awareness of hypoglycaemia in people who have had a severe hypoglycaemic emergency and been attended by the ambulance service [PDF]
, 2017 Edward Duncan +2 more
openalex +1 more source
Multifocal insulinoma secondary to insulinomatosis: persistent hypoglycaemia despite total pancreatectomy [PDF]
, 2020 Jennifer Snaith +3 more
openalex +1 more source
Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe
ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani +11 more
wiley +1 more source
Liraglutide for the treatment of type 2 diabetes : a single technology appraisal [PDF]
, 2011 This paper presents a summary of the Evidence Review Group (ERG) report into the clinical effectiveness and cost-effectiveness of liraglutide in the treatment of type 2 diabetes mellitus, based upon the manufacturer’s submission to the National ...
Cummins, E. (Ewen) +3 more
core
Can somatostatin antagonism prevent hypoglycaemia during exercise in type 1 diabetes? [PDF]
, 2016 Nadine Taleb, Rémi Rabasa‐Lhoret
openalex +1 more source
Managing Hypoglycaemia in Young People with Type 1 Diabetes with an Eating Disorder (T1DE) [PDF]
, 2023 Team DFTB
openalex +1 more source
Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis
ESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen +7 more
wiley +1 more source
Environmental and Molecular Mutagenesis, EarlyView.Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons +17 more
wiley +1 more source